ArticleBMC cancer2026
Oxalate induces proliferation and mitochondrial metabolism in select clear cell renal cell carcinoma cell lines.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Renal Cell Carcinoma (RCC) leads to over $3 billion in annual healthcare costs and reduces patients' quality of life. While the causes of RCC are not fully understood, studies suggest a link to kidney stone (KS) disease, particularly those containing calcium oxalate (CaOx). Oxalate is found in certain plant-derived foods and is known to cause oxidative stress, inflammation, and cancer-like properties in renal epithelial cells. However, its effect on RCC remains unclear. This study investigated the impact of oxalate on clear cell RCC (ccRCC), the most common RCC subtype, using two ccRCC cell lines: 786-O (ccB subtype) and 769-P (ccA subtype). We hypothesized that oxalate promotes tumor-like behavior in ccRCC cells. After exposing cells to both soluble and insoluble oxalate for 24 h, we measured cell proliferation, metabolism, oxidative stress, and DNA damage. In 786-O cells, oxalate increased proliferation, mitochondrial gene expression, and metabolism, while reducing oxidative stress. In contrast, oxalate had little effect on 769-P proliferation or metabolism but increased oxidative stress and DNA damage. To determine if these effects were subtype-specific, we treated Caki-1 cells (another ccB subtype) and observed similar responses to 786-O cells. Importantly, rapamycin, an mTOR inhibitor, prevented oxalate-induced responses in 786-O and Caki-1 cells. These findings suggest that oxalate enhances proliferation and metabolic activity in certain ccRCC subtypes and may contribute to the association between RCC and KS disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.